SCHEMBL3350405

SCHEMBL3350405

CNC(=O)c1cc(C(N)=O)cc(-c2nccs2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK2 O96017 2/20 0.47
HDAC2 Q92769 2/20 0.43
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
HDAC9 Q9UKV0 1/20 0.41
HDAC5 Q9UQL6 1/20 0.41
SMPD3 Q9NY59 1/20 0.41
LRRK2 Q5S007 1/20 0.41
KAT6A Q92794 1/20 0.40
MYC P01106 1/20 0.40
SIRT2 Q8IXJ6 1/20 0.39
SIRT1 Q96EB6 1/20 0.39
SIRT3 Q9NTG7 1/20 0.39
ADRB2 P07550 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3347232 0.83 SMN1; SMN2 (0.44) CHEK2HDAC2HDAC3HDAC4HDAC1
SCHEMBL2733047 0.79 KAT6A (0.61) HDAC2HDAC3HDAC4HDAC1HDAC7
SCHEMBL3350750 0.76 CHEK2 (0.43) CHEK2HDAC2SMPD3LRRK2MYC
SCHEMBL3350408 0.75 SMPD3 (0.46) CHEK2HDAC2HDAC3HDAC4HDAC1
Hydrochloric Acid SCHEMBL3349089 0.75 CHEK2 (0.42) CHEK2HDAC2SMPD3LRRK2MYC
Hydrochloric Acid SCHEMBL3351582 0.75 CHEK2 (0.42) CHEK2HDAC2SMPD3LRRK2MYC
SCHEMBL2303493 0.74 KAT6A (0.55) CHEK2HDAC2HDAC3HDAC4HDAC1
SCHEMBL2592323 0.72 CHEK2 (0.68) CHEK2HDAC2HDAC3HDAC4HDAC1
SCHEMBL3347776 0.72 GLRA3 (0.48) HDAC4HDAC8HDAC6BRD4
SCHEMBL6645375 0.70 MAPK1 (0.43) HDAC2SMPD3KAT6ASMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7727997-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2010-06-01 US disclosed
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease BACE1, BACE2, APP CHEK2 3158/4885HDAC2 833/4885HDAC3 527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.